Collegium Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Collegium Pharmaceutical
COLL Stock  USD 45.14  1.19  2.71%   
Collegium Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Collegium Pharmaceutical's valuation are provided below:
Gross Profit
667.5 M
Profit Margin
0.0772
Market Capitalization
1.4 B
Enterprise Value Revenue
2.5803
Revenue
757.1 M
There are over one hundred nineteen available fundamental signals for Collegium Pharmaceutical, which can be analyzed over time and compared to other ratios. We recommend to validate Collegium Pharmaceutical's prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 970.9 M this year. Enterprise Value is expected to rise to about 1.9 B this year

Collegium Pharmaceutical Total Revenue

663.02 Million

Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 177.6 M, Interest Expense of 77.7 M or Selling General Administrative of 105.2 M, as well as many indicators such as Price To Sales Ratio of 1.39, Dividend Yield of 0.0721 or PTB Ratio of 5.12. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Collegium Stock
Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Collegium Pharmaceutical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.7 B1.7 B506.1 M
Slightly volatile
Short and Long Term Debt Total902.3 M859.3 M233.3 M
Slightly volatile
Total Current Liabilities535 M509.5 M182.8 M
Slightly volatile
Other Liabilities816.3 K777.4 K456.5 K
Slightly volatile
Property Plant And Equipment Net14.5 M20.2 M10.9 M
Slightly volatile
Accounts Payable7.5 M3.9 M5.8 M
Slightly volatile
Cash140.9 M70.6 M106.3 M
Slightly volatile
Non Current Assets Total1.2 B1.2 B289.9 M
Slightly volatile
Non Currrent Assets Other9.9 M9.4 M1.8 M
Slightly volatile
Other Assets21.1 M22.2 M64.1 M
Pretty Stable
Cash And Short Term Investments155.9 M162.8 M117.5 M
Slightly volatile
Common Stock Total Equity29.4 K42.5 K23.7 K
Slightly volatile
Common Stock Shares Outstanding31.3 M40.4 M24.7 M
Slightly volatile
Liabilities And Stockholders Equity1.7 B1.7 B506.1 M
Slightly volatile
Non Current Liabilities Total971.5 M925.2 M213.6 M
Slightly volatile
Other Current Assets58.2 M55.4 M9.9 M
Slightly volatile
Other Stockholder Equity371.9 M392.7 M279.1 M
Slightly volatile
Total Liabilities1.5 B1.4 B396 M
Slightly volatile
Property Plant And Equipment Gross35.4 M33.7 M13.7 M
Slightly volatile
Total Current Assets268.4 M482.3 M201.3 M
Slightly volatile
Short Term Debt48.6 M65.9 M36.3 M
Slightly volatile
Common Stock31.6 K40 K23.7 K
Slightly volatile
Property Plant Equipment23.6 M22.4 M10 M
Slightly volatile
Net Receivables240 M228.5 M74.8 M
Slightly volatile
Short and Long Term Debt52 M64.6 M36 M
Slightly volatile
Long Term Debt Total650.2 M619.2 M175.7 M
Slightly volatile
Capital Surpluse468.8 M618.8 M381.6 M
Slightly volatile
Capital Lease Obligations7.9 M6.8 M4.9 M
Slightly volatile
Non Current Liabilities Other1.3 M1.4 M2.4 M
Slightly volatile
Net Invested Capital1.1 B1.1 B357.2 M
Slightly volatile
Capital Stock39.8 K40 K34.8 K
Slightly volatile

Collegium Pharmaceutical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization177.6 M169.2 M55.9 M
Slightly volatile
Interest Expense77.7 M74 M23.2 M
Slightly volatile
Selling General Administrative105.2 M172.3 M78.7 M
Slightly volatile
Other Operating Expenses246.3 M461.6 M186.3 M
Slightly volatile
Total Operating Expenses120.9 M207.4 M93 M
Slightly volatile
Interest Income14.7 M14 M3.2 M
Slightly volatile
Selling And Marketing Expenses10.1 M10.7 M59.4 M
Slightly volatile
Reconciled Depreciation98.3 M169.2 M51.1 M
Slightly volatile
Non Recurring3.7 M4.1 M4.5 M
Slightly volatile

Collegium Pharmaceutical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34 M32.4 M13.1 M
Slightly volatile
Begin Period Cash Flow136.3 M240 M103.7 M
Slightly volatile
Depreciation177.6 M169.2 M55.9 M
Slightly volatile
Capital Expenditures1.6 M1.7 M26.1 M
Pretty Stable
End Period Cash Flow144.1 M96.6 M108.7 M
Slightly volatile
Dividends Paid10.5 M8.2 M15.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.391.464398.7783
Slightly volatile
Dividend Yield0.07210.07480.0664
Slightly volatile
Days Sales Outstanding171132269
Slightly volatile
Stock Based Compensation To Revenue0.04870.05131.5259
Slightly volatile
Capex To Depreciation0.00930.00981.2511
Pretty Stable
EV To Sales2.762.904460.6931
Slightly volatile
Inventory Turnover6.987.14585.4048
Slightly volatile
Days Of Inventory On Hand48.5251.07891 K
Slightly volatile
Payables Turnover67.8264.59220.0911
Slightly volatile
Sales General And Administrative To Revenue0.360.27290.3444
Slightly volatile
Research And Ddevelopement To Revenue0.00940.00993.8515
Slightly volatile
Capex To Revenue0.00250.00260.8466
Slightly volatile
Cash Per Share3.865.04324.0465
Slightly volatile
Days Payables Outstanding5.375.65093.9 K
Slightly volatile
Intangibles To Total Assets0.670.63340.2367
Slightly volatile
Current Ratio0.90.94653.1859
Slightly volatile
Receivables Turnover2.322.7632.0785
Slightly volatile
Graham Number11.6418.49411.2965
Slightly volatile
Capex Per Share0.04860.05120.7692
Pretty Stable
Revenue Per Share20.5419.56536.6489
Slightly volatile
Interest Debt Per Share34.2932.65458.6495
Slightly volatile
Debt To Assets0.520.5890.402
Pretty Stable
Operating Cycle1741831.3 K
Slightly volatile
Days Of Payables Outstanding5.375.65093.9 K
Slightly volatile
Total Debt To Capitalization0.770.81071.3953
Pretty Stable
Quick Ratio0.830.87673.1394
Slightly volatile
Cash Ratio0.130.13852.7214
Slightly volatile
Days Of Inventory Outstanding48.5251.07891 K
Slightly volatile
Days Of Sales Outstanding171132269
Slightly volatile
Fixed Asset Turnover32.931.335912.5413
Slightly volatile
Debt Ratio0.520.5890.402
Pretty Stable
Price Sales Ratio1.391.464398.7783
Slightly volatile
Asset Turnover0.380.37960.2967
Slightly volatile
Gross Profit Margin0.650.59760.6995
Slightly volatile

Collegium Pharmaceutical Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap970.9 M924.6 M521.3 M
Slightly volatile
Enterprise Value1.9 B1.8 B657.9 M
Slightly volatile

Collegium Fundamental Market Drivers

Forward Price Earnings5.9312
Cash And Short Term Investments162.8 M

Collegium Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Collegium Pharmaceutical Financial Statements

Collegium Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Collegium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue10 M10.5 M
Total Revenue631.4 M663 M
Cost Of Revenue254.1 M136.8 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.27  0.36 
Research And Ddevelopement To Revenue 0.01  0.01 
Revenue Per Share 19.57  20.54 
Ebit Per Revenue 0.27  0.28 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
How To Invest In Collegium
Details
Is Collegium Stock a good investment?
Details
What is Collegium Pharmaceutical's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.132
Earnings Share
1.63
Revenue Per Share
23.798
Quarterly Revenue Growth
0.314
Return On Assets
0.0675
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY